Syros Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Syros Pharmaceuticals has a total shareholder equity of $16.7M and total debt of $41.2M, which brings its debt-to-equity ratio to 247.4%. Its total assets and total liabilities are $168.2M and $151.5M respectively.
Key information
247.4%
Debt to equity ratio
US$41.22m
Debt
| Interest coverage ratio | n/a |
| Cash | US$139.53m |
| Equity | US$16.66m |
| Total liabilities | US$151.51m |
| Total assets | US$168.17m |
Recent financial health updates
Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 08
Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?
May 07Recent updates
Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Syros Pharmaceuticals Is A Buy As New Trials Start
Nov 20Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 08Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 02Syros Pharma up 18% day after ARK Innovation dumps shares
May 27Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts
May 11Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?
May 07Financial Position Analysis
Short Term Liabilities: SYRS's short term assets ($145.0M) exceed its short term liabilities ($36.7M).
Long Term Liabilities: SYRS's short term assets ($145.0M) exceed its long term liabilities ($114.8M).
Debt to Equity History and Analysis
Debt Level: SYRS has more cash than its total debt.
Reducing Debt: SYRS's debt to equity ratio has increased from 0% to 247.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SYRS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 20.7% each year.